tiprankstipranks
Trending News
More News >
SAB Biotherapeutics (SABS)
NASDAQ:SABS
US Market

SAB Biotherapeutics (SABS) Income Statement

Compare
140 Followers

SAB Biotherapeutics Income Statement

Last quarter (Q4 2024), SAB Biotherapeutics's total revenue was $114.70K, a decrease of -62.40% from the same quarter last year. In Q4, SAB Biotherapeutics's net income was $-11.39M. See SAB Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 1.32M$ 2.24M$ 23.90M$ 60.88M$ 55.24M
Gross Profit
$ -3.47M$ -1.51M$ 20.61M$ 59.22M$ 55.24M
Operating Expenses
$ 42.91M$ 36.57M$ 28.92M$ 13.39M$ 34.68M
Depreciation and Amortization
$ 4.79M$ 3.75M$ 3.29M$ 1.65M$ 548.18K
EBITDA
$ -28.99M$ -38.13M$ -15.12M$ -15.20M$ 21.14M
Operating Income
$ -42.91M$ -38.08M$ -28.92M$ -13.39M$ 20.56M
Other Income/Expenses
$ 8.81M$ -4.12M$ 10.20M$ -3.75M$ -439.02K
Pretax Income
$ -34.11M$ -42.19M$ -18.72M$ -17.14M$ 20.12M
Net Income
$ -34.11M$ -42.19M$ -18.74M$ -17.44M$ 20.12M
Per Share Metrics
Basic EPS
$ -3.68$ -7.64$ -4.31$ -6.38$ 7.92
Diluted EPS
$ -3.68$ -7.64$ -4.31$ -6.38$ 7.45
Weighted Average Shares Outstanding
9.26M 5.52M 4.35M 2.73M 2.54M
Weighted Average Shares Outstanding (Diluted)
9.26M 5.52M 4.35M 2.73M 2.70M
Currency in USD

SAB Biotherapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis